Business Description
Infinity Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US45665G3039
Description
Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 28.04 | |||||
| Equity-to-Asset | -1.76 | |||||
| Debt-to-Equity | -0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -63.58 | |||||
| Beneish M-Score | -3.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -18.7 | |||||
| 3-Year EBITDA Growth Rate | 14.3 | |||||
| 3-Year EPS without NRI Growth Rate | 15.5 | |||||
| 3-Year FCF Growth Rate | 14.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | -5.52 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.9 | |||||
| 9-Day RSI | 18.35 | |||||
| 14-Day RSI | 24.39 | |||||
| 6-1 Month Momentum % | -56 | |||||
| 12-1 Month Momentum % | -91.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.65 | |||||
| Quick Ratio | 1.65 | |||||
| Cash Ratio | 1.47 | |||||
| Days Payable | 547.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.1 | |||||
| Shareholder Yield % | 2.82 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 39.7 | |||||
| Operating Margin % | -1636.67 | |||||
| Net Margin % | -1593.93 | |||||
| ROA % | -99.01 | |||||
| ROIC % | -689.26 | |||||
| ROC (Joel Greenblatt) % | -2727.32 | |||||
| ROCE % | -144.3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.61 | |||||
| EV-to-EBIT | 0.37 | |||||
| EV-to-EBITDA | 0.38 | |||||
| EV-to-Revenue | -5.92 | |||||
| EV-to-Forward-Revenue | 2 | |||||
| EV-to-FCF | 0.39 | |||||
| Earnings Yield (Greenblatt) % | 270.27 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:INFI
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Infinity Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.569 | ||
| EPS (TTM) ($) | -0.46 | ||
| Beta | 1.19 | ||
| Volatility % | 98.62 | ||
| 14-Day RSI | 24.39 | ||
| 14-Day ATR ($) | 0.013383 | ||
| 20-Day SMA ($) | 0.063478 | ||
| 12-1 Month Momentum % | -91.93 | ||
| 52-Week Range ($) | 0.01555 - 1.3 | ||
| Shares Outstanding (Mil) | 90.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Infinity Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Infinity Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Infinity Pharmaceuticals Inc Frequently Asked Questions
What is Infinity Pharmaceuticals Inc(INFI)'s stock price today?
The current price of INFI is $0.02. The 52 week high of INFI is $1.30 and 52 week low is $0.02.
When is next earnings date of Infinity Pharmaceuticals Inc(INFI)?
The next earnings date of Infinity Pharmaceuticals Inc(INFI) is 2023-11-14 Est..
Does Infinity Pharmaceuticals Inc(INFI) pay dividends? If so, how much?
Infinity Pharmaceuticals Inc(INFI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers